诊疗指南

2014 AGA指南:肠易激综合征的药物疗法

The American Gastroenterological Association’s 2014 guideline on pharmacologic management of irritable bowel syndrome.
2016-02-01 18:20 点击次数:649发表评论

Irritable bowel syndrome is complex and encompasses several subgroups, including patients with constipation-predominant symptoms and those with diarrhea-predominant symptoms. The recommendations in this guideline apply to patients who meet the diagnostic criteria for IBS. Use of nonpharmaceutical agents (eg, fiber) and other interventions (eg, dietary modification, biofeedback, acupuncture) for treatment of patients with IBS was not covered. For constipation-predominant IBS, linactolide is strongly recommended (high-quality evidence); lubiprostone is conditionally recommended (moderate-quality evidence); and polyethylene glycol (PEG) laxatives are conditionally recommended (low-quality evidence). For diarrhea-predominant IBS, rifaximin and alosteron are conditionally recommended (moderate-quality evidence) and loperamide is conditionally recommended (very low-quality evidence). For IBS in general, tricyclic antidepressants and antispasmodics are conditionally recommended (low-quality evidence). The guideline recommends against use of selective serotonin reuptake inhibitors (SSRIs) for management of IBS (low-quality evidence).

    
学科代码:消化病学   关键词:肠易激综合征 ,指南 爱思唯尔医学网, Elseviermed
顶一下(0
您可能感兴趣的指南
    发表评论网友评论(0)
      发表评论
      登录后方可发表评论,点击此处登录